Physiomics PLC Senior Management Announcement
03 10월 2023 - 3:00PM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
03 October 2023
3 October 2023
Physiomics plc
("Physiomics" or "the Company")
Senior Management Announcement
Physiomics plc (AIM: PYC), the oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions, is pleased to
announce the hiring this week of a new senior member of its team,
Dr Venkata Putcha, as Head of Biostatistics.
Dr Putcha brings with him over 22 years of experience working
within drug development, with over 17 years working for many of the
top-tier pharmaceutical and CRO companies. Since obtaining his PhD
in Applied Statistics, he has held a variety of senior
biostatistics and programming roles across academia and industry,
both working in-house and as an independent consultant. During
these roles, he gained significant experience across Pre-clinical,
PK/PD, Biosimilars, Phase-I, IIa, IIb, III and IV, Medical Affairs,
Post-Marketing, Diagnostics, Medical Devices, Heath Technology
Assessments, Health Economics and Health Related Quality of Life
analysis.
The Head of Biostatistics role will help to formulate and
deliver on the Company's new Biostatistics service offering. The
initial focus will be to build upon the Company's existing
Biostatistics strategy, working with Business Development and
Senior Management to define key service offerings and identify new
clients. Dr Putcha will be responsible for the delivery of new
Biostatistics consulting contracts within the business and, as we
grow this service line, will take a lead refining and executing on
the Company's Biostatistics strategy.
Dr Jim Millen, Executive Chair and CEO commented :
"Following our announcement earlier this year that Physiomics
would be expanding into adjacent areas of lifesciences R&D
consulting, starting with biostatistics, we are delighted to
welcome Venkata to our team. His extensive experience in the field
of biostatistics will act as a strong base from which to grow this
new segment of our business. We'll be providing a further update on
our expansion into this field later this calendar year."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling
techniques with cancer biology expertise, to help biotech and
pharma companies streamline their drug development journeys.
Our approach is to derive insight from all relevant data in
order to de-risk decision making and optimise design of
pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour
technology, the Physiomics team has informed the development of
over 100 commercial projects, over 50 targets and 75 drugs. Clients
include Merck KGaA, Astellas, Bicycle Therapeutics, Numab
Therapeutics & CRUK.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADLLFBXBLEFBX
(END) Dow Jones Newswires
October 03, 2023 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Physiomics (LSE:PYC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024